Vagus Nerve Stimulation with Mild Stimulation Intensity Exerts Anti-Inflammatory and Neuroprotective Effects in Parkinson's Disease Model Rats.
Parkinson’s disease
anti-inflammation
less invasive therapy
new experimental device
vagus nerve stimulation
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
07 07 2021
07 07 2021
Historique:
received:
13
06
2021
revised:
02
07
2021
accepted:
05
07
2021
entrez:
6
8
2021
pubmed:
7
8
2021
medline:
7
8
2021
Statut:
epublish
Résumé
The major surgical treatment for Parkinson's disease (PD) is deep brain stimulation (DBS), but a less invasive treatment is desired. Vagus nerve stimulation (VNS) is a relatively safe treatment without cerebral invasiveness. In this study, we developed a wireless controllable electrical stimulator to examine the efficacy of VNS on PD model rats. Adult female Sprague-Dawley rats underwent placement of a cuff-type electrode and stimulator on the vagus nerve. Following which, 6-hydroxydopamine (6-OHDA) was administered into the left striatum to prepare a PD model. VNS was started immediately after 6-OHDA administration and continued for 14 days. We evaluated the therapeutic effects of VNS with behavioral and immunohistochemical outcome assays under different stimulation intensity (0.1, 0.25, 0.5 and 1 mA). VNS with 0.25-0.5 mA intensity remarkably improved behavioral impairment, preserved dopamine neurons, reduced inflammatory glial cells, and increased noradrenergic neurons. On the other hand, VNS with 0.1 mA and 1 mA intensity did not display significant therapeutic efficacy. VNS with 0.25-0.5 mA intensity has anti-inflammatory and neuroprotective effects on PD model rats induced by 6-OHDA administration. In addition, we were able to confirm the practicality and effectiveness of the new experimental device.
Sections du résumé
BACKGROUND
The major surgical treatment for Parkinson's disease (PD) is deep brain stimulation (DBS), but a less invasive treatment is desired. Vagus nerve stimulation (VNS) is a relatively safe treatment without cerebral invasiveness. In this study, we developed a wireless controllable electrical stimulator to examine the efficacy of VNS on PD model rats.
METHODS
Adult female Sprague-Dawley rats underwent placement of a cuff-type electrode and stimulator on the vagus nerve. Following which, 6-hydroxydopamine (6-OHDA) was administered into the left striatum to prepare a PD model. VNS was started immediately after 6-OHDA administration and continued for 14 days. We evaluated the therapeutic effects of VNS with behavioral and immunohistochemical outcome assays under different stimulation intensity (0.1, 0.25, 0.5 and 1 mA).
RESULTS
VNS with 0.25-0.5 mA intensity remarkably improved behavioral impairment, preserved dopamine neurons, reduced inflammatory glial cells, and increased noradrenergic neurons. On the other hand, VNS with 0.1 mA and 1 mA intensity did not display significant therapeutic efficacy.
CONCLUSIONS
VNS with 0.25-0.5 mA intensity has anti-inflammatory and neuroprotective effects on PD model rats induced by 6-OHDA administration. In addition, we were able to confirm the practicality and effectiveness of the new experimental device.
Identifiants
pubmed: 34356853
pii: biomedicines9070789
doi: 10.3390/biomedicines9070789
pmc: PMC8301489
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : the Ministry of Health, Labor, and Welfare of Japan
ID : 09156274 and 24592129
Références
J Neurotrauma. 2006 Oct;23(10):1549-60
pubmed: 17020489
Stroke. 2016 Jan;47(1):143-50
pubmed: 26645257
Neurosci Lett. 2005 May 13;379(3):174-9
pubmed: 15843058
Transl Neurodegener. 2015 Oct 12;4:19
pubmed: 26464797
Cell. 2018 Oct 18;175(3):665-678.e23
pubmed: 30245012
Neurorehabil Neural Repair. 2016 Aug;30(7):676-84
pubmed: 26542082
Arch Neurol. 2003 Mar;60(3):337-41
pubmed: 12633144
Cereb Cortex. 2012 Oct;22(10):2365-74
pubmed: 22079923
Stroke. 2001 Nov;32(11):2648-57
pubmed: 11692030
Front Aging Neurosci. 2020 Jun 16;12:164
pubmed: 32612523
Neuroreport. 2014 Jun 18;25(9):676-82
pubmed: 24818637
J Inflamm Res. 2018 May 16;11:203-213
pubmed: 29844694
Nutrition. 2015 Nov-Dec;31(11-12):1416-22
pubmed: 26429664
J Neurol Sci. 2006 Oct 25;248(1-2):35-41
pubmed: 16753180
Basic Res Cardiol. 2015 Sep;110(5):508
pubmed: 26306761
Lancet Neurol. 2009 Apr;8(4):382-97
pubmed: 19296921
BMB Rep. 2010 Apr;43(4):225-32
pubmed: 20423606
Inflammation. 2011 Feb;34(1):29-35
pubmed: 20336357
Mol Neurobiol. 2014 Feb;49(1):28-38
pubmed: 23783559
Neurology. 2001 Aug 14;57(3):456-62
pubmed: 11502913
Brain Res. 2021 Apr 1;1756:147332
pubmed: 33539792
Epilepsia. 2017 Apr;58 Suppl 1:85-90
pubmed: 28386925
J Neuroinflammation. 2012 Jul 25;9:183
pubmed: 22830560
Brain Stimul. 2016 Jan-Feb;9(1):117-23
pubmed: 26460200
Neuropharmacology. 2000 Mar 3;39(5):777-87
pubmed: 10699444
Brain Stimul. 2020 Sep - Oct;13(5):1323-1332
pubmed: 32629028
Neurogastroenterol Motil. 2017 Sep;29(9):
pubmed: 28429863
J Neurotrauma. 2016 May 1;33(9):871-9
pubmed: 26058501
Brain Stimul. 2017 Nov - Dec;10(6):1045-1054
pubmed: 28918943
J Neurotrauma. 2005 Dec;22(12):1485-502
pubmed: 16379585
Sci Transl Med. 2018 Oct 31;10(465):
pubmed: 30381408
J Neuroinflammation. 2013 Jul 09;10:81
pubmed: 23837880
J Clin Psychiatry. 2006 Aug;67(8):1171-8
pubmed: 16965193
Shock. 2013 Aug;40(2):144-51
pubmed: 23860583
Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):6058-63
pubmed: 20231476
Stroke. 2014 Oct;45(10):3097-100
pubmed: 25147331
Prog Brain Res. 2013;207:275-99
pubmed: 24309259
Neuroscience. 1993 Jan;52(1):1-6
pubmed: 8433802
Brain Stimul. 2016 Mar-Apr;9(2):166-73
pubmed: 26723020
Am J Manag Care. 2017 Nov;23(17 Suppl):S312-S316
pubmed: 29144716
J Neurol Neurosurg Psychiatry. 2013 Jul;84(7):774-83
pubmed: 23064099
Nature. 2011 Feb 3;470(7332):101-4
pubmed: 21228773
Glia. 2015 Jun;63(6):1057-72
pubmed: 25740080
Pain Rep. 2017 Oct 17;2(6):e628
pubmed: 29392242
Brain Res. 2006 Nov 13;1119(1):124-32
pubmed: 16962076
Acta Neurol Scand. 2016 Mar;133(3):173-82
pubmed: 26190515
J Neural Transm (Vienna). 2003 May;110(5):517-36
pubmed: 12721813
Nat Rev Rheumatol. 2016 Sep;12(9):500
pubmed: 27440426
Brain Stimul. 2020 Nov - Dec;13(6):1617-1630
pubmed: 32956868
Brain Res. 2009 Feb 13;1254:120-7
pubmed: 19101524
Exp Neurol. 2016 Jan;275 Pt 1:220-31
pubmed: 26555088
Epilepsia. 1998 Jul;39(7):709-14
pubmed: 9670898
J Neural Eng. 2013 Apr;10(2):026003
pubmed: 23370017
J Neurosurg. 2014 Jan;120(1):132-9
pubmed: 24236657
PLoS One. 2012;7(11):e42799
pubmed: 23189120
Neurology. 2017 May 23;88(21):1996-2002
pubmed: 28446653
Neurology. 2018 Jul 24;91(4):e364-e373
pubmed: 29907608
Nat Rev Neurol. 2012 May 15;8(6):329-39
pubmed: 22584158
Neurology. 1988 Aug;38(8):1285-91
pubmed: 3399080
J Physiol. 2016 Oct 15;594(20):5781-5790
pubmed: 27059884
Brain. 2011 Mar;134(Pt 3):665-77
pubmed: 21297130
Neurosci Biobehav Rev. 2000 Aug;24(6):655-68
pubmed: 10940440
Neurosci Lett. 2009 Aug 14;459(3):147-51
pubmed: 19446004
Neural Regen Res. 2014 Sep 1;9(17):1585-91
pubmed: 25368644
Front Behav Neurosci. 2012 Jul 25;6:48
pubmed: 22848194
J Parkinsons Dis. 2019;9(1):17-29
pubmed: 30741691
Exp Physiol. 2015 Jan;100(1):57-68
pubmed: 25398717
PLoS One. 2014 Jul 10;9(7):e101468
pubmed: 25009993
Crit Care Med. 2007 Dec;35(12):2762-8
pubmed: 17901837
Stereotact Funct Neurosurg. 2003;80(1-4):28-31
pubmed: 14745205